Categories AlphaGraphs, Earnings, Health Care
AngioDynamics (ANGO) Q3 2025 loss narrows; sales down 4%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) Wednesday reported a narrower net loss for the third quarter of 2025. Revenues decreased by 4%.
Net loss, excluding special items, was $0.08 per share in the February quarter, compared to a loss of $0.16 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $4.41 million or $0.11 per share in Q2 from $187.7 million or $4.67 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 4% year-over-year to $72.0 million in the third quarter. The company expects fiscal 2025 sales to be in the range of $285 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “Based on the quality of performance
we have seen through fiscal 2025, we are increasing our fiscal full-year guidance for all of our key metrics, including; total worldwide revenue, MedTech revenue growth, gross margin, adjusted EBITDA, and adjusted EPS.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Here’s why Dollar General (DG) is well-positioned for meaningful growth ahead
Shares of Dollar General Corporation (NYSE: DG) rose over 6% on Friday. The stock has gained 76% year-to-date. The discount store chain delivered robust results for the third quarter of
Docusign (DOCU) Earnings: 3Q26 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported its earnings results for the third quarter of 2026. Revenue increased 8% year-over-year to $818.4 million. GAAP net income was $83.7 million, or $0.40
Infographic: How Ulta Beauty (ULTA) performed in Q3 2025
Ulta Beauty, Inc. (NASDAQ: ULTA) reported its earnings results for the third quarter of 2025. Net sales increased 12.9% year-over-year to $2.9 billion, driven by comparable sales growth, the Space
